Concept and Practice of Therapeutic Teams

Preface; Part I. Introduction: 1. Introductory remarks; Part II. The Concept of the Theraputic Team: 2. The concept of the therapeutic team; 3. The view of a pharmacist; 4. The view of a physician; 5. The view of a nurse; 6. The view of the clinical pharmacologist; 7. The view of an academic; Part III. Practice of the Therapeutic Team: Parenteral Nutrition: 8. Parenteral nutrition - the team approach in a general hospital; 9. Long-term follow-up in total parenteral nutrition; 10. Total parenteral nutrition of children at the State University Hospital of Copenhagen; 11. Compatibility of two different fat emulsions with amino-acids, carbohydrate and electrolytes in parenteral nutrition mixtures; 12. Esophagus cancer and parenteral nutrition: postoperative complications and P. N. I. relationship. Preliminary study; Part IV. Oncology: 13. Central nervous system prohylaxis of acute lymphoblastic leukemia with methotrexate; 14. The treatment protocols of acute lymphoblastic leukemia in children; 15. Guidelines for the safe handling of minibags; 16. Centralization of preparation of cytotoxic drugs in the central pharmacy: one year of experience; 17. Progress in the management of high dose methotrexate; 18. Parmacokinetics of cytosine arabinoside in leukemic patients with normal and impaired hepatic functions, preliminary results; PartV. Dermatology: 19. The operation of a therapeutic team in dermatology; Part VI. Epilepsy: 20. Team treatment of epilepsy; 21. Practices of the therapeutic team in epilepsy; 22. Interdisciplinary approach to the treatment of epilepsy; 23. The role of clinical pharmacist in the monitoring of antiepileptic therapy in clinics with ambulant patients, our experience with 45 patients; Part VII. Internal Medicine - Rheumatology: 24. An approach to the therapeutic strategy in rheumatoid arthritis. Adverse reactions to penicillamine-like drugs used in the treatment of rheumatoid arthritis; Part VIII. Nuclear Medicine: 25. The nuclear medicine team; 26. Practice of the nuclear medicine therapeutic team: the role of the physician; 27. Practice of the nuclear medicine therapeutic team: the role of the physicist; 28. Practice of the nuclear medicine therapeutic team: the role of the radiotherapist; Part IX. Drug Selection: 29. Collaboration in drug selection - preparing the London Hospital Formulary 1982 - guide to the prescribing of medicines: introduction; 30. A clinician's view on the team approach to drug selection; 31. A pharmacists view on the team approach to drug selection; 32. Conclusion; 33. Restrictive formulary management with consequences for the treatment of individual patients; 34. Changes in patterns of analgesic use; Part X. Pharmacokinetics, Dialysis, I. V. Therapy: 35. Clinical pharmacy improvement and interrelation with therapeutci team; 36. Clinical pharmacist participation in a clinical trial - treatment of congestive heart failure; 37. Metronidazole plasma levels after I. V. and rectal administration; 38. Individual factors influencing aminoglycoside serum levels; 39. Monitoring theophylline plasma levels; 40. Comparison of four pharmacokinetic methods for individualizing phenytoin dosage; 41. Use of a calculator program for individualized estimation of pheyoin kinetic parameters by a least-squares technique; 42. On the importance of regular Al determination in patients on regular hemodialysis (RHD); 43. Manufacture of dialysis concentrate at the level of a hospital; 44. Hospital preparation of injectable drugs by means of a multi-additive pump; 45. How to detect physico-chemical incompatabilities in I. V. admixtures; 46. Preparation of an enema containing metaminosalicylic acid